Braveheart Bio, Inc. (NASDAQ:BRVE) Stock Has Consensus Target Price of $45.25 According to Brokerages

Shares of Braveheart Bio, Inc. (NASDAQ:BRVE) have been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $45.25.

A number of analysts have recently issued reports on the stock. Jefferies Financial Group assumed coverage on shares of Braveheart Bio in a research note on Monday, August 31st. They set a “buy” rating and a $48.00 target price for the company. Zacks Research upgraded shares of Braveheart Bio to a “hold” rating in a report on Tuesday, September 1st. TD Cowen assumed coverage on shares of Braveheart Bio in a research report on Monday, August 31st. They issued a “buy” rating for the company. Stifel Nicolaus began coverage on shares of Braveheart Bio in a research note on Monday, August 31st. They issued a “buy” rating and a $45.00 target price on the stock. Finally, The Goldman Sachs Group started coverage on Braveheart Bio in a report on Monday, August 31st. They set a “buy” rating and a $48.00 price objective on the stock.

Insider Buying and Selling at Braveheart Bio

In other Braveheart Bio news, Director Orbimed Advisors Llc acquired 1,940,000 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was bought at an average cost of $18.00 per share, with a total value of $34,920,000.00. Following the completion of the purchase, the director directly owned 11,901,826 shares in the company, valued at $214,232,868. The trade was a 19.47% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christopher Viehbacher bought 83,333 shares of the company’s stock in a transaction on Friday, August 7th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $1,499,994.00. Following the completion of the acquisition, the director owned 609,519 shares in the company, valued at $10,971,342. This represents a 15.84% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have purchased 8,751,942 shares of company stock worth $157,534,956.

Braveheart Bio Stock Up 8.9%

Shares of BRVE stock opened at $23.37 on Friday. Braveheart Bio has a 52-week low of $20.69 and a 52-week high of $32.00.

Braveheart Bio (NASDAQ:BRVE) last announced its quarterly earnings data on Tuesday, September 8th. The company reported ($2.51) EPS for the quarter, missing the consensus estimate of ($0.25) by ($2.26). On average, research analysts expect that Braveheart Bio will post -1.48 EPS for the current fiscal year.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.